Clinical Trials on Stage III Hypopharyngeal Carcinoma AJCC v8

Total 2292 results

National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Not yet recruiting

Biomarkers in Samples From Patients With Endometrial Cancer

Lynch Syndrome | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer

United States
Centre Oscar Lambret
Institut National de la Santé Et de la Recherche Médicale, France

Recruiting

Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer (TILsOV-1805)

Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Fallopian Tube Cancer Stage IIIC | Fallopian Tube Cancer Stage IV

France
City of Hope Medical Center

Recruiting

Early Detection of Advanced Adenomas and Colorectal Cancer (AACRC)

Colorectal Neoplasms | Colorectal Cancer | Colorectal Disorders | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Polyp | Colorectal Neoplasms Malignant | Colorectal Adenomatous Polyp | Colorectal Cancer Stage I | Colorectal Adenoma... and other conditions

United States, Italy, China, Spain, Japan
National Cancer Institute (NCI)

Terminated

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Stage IV Melanoma | Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Stage... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
ETOP IBCSG Partners Foundation
Roche Pharma AG

Active, not recruiting

ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (ABC-lung)

EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC

Singapore, Spain, Korea, Republic of, Switzerland, Germany
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7 | EGFR Exon 19 Deletion Mutation | EGFR NP_005219.2:p.L858R

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

Human Papilloma Virus Infection | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IVA Squamous Cell Carcinoma of the Oropharynx | Stage IVB Squamous Cell Carcinoma of the Oropharynx

United States
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer (OPTIMA)

Human Papilloma Virus Infection | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IVA Squamous Cell Carcinoma of the Oropharynx | Stage IVB Squamous Cell Carcinoma of the Oropharynx

United States
Krystal Biotech, Inc.

Recruiting

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Cancer | Carcinoma, Squamous Cell | Carcinoma, Basal Cell | Osteosarcoma | Cutaneous Melanoma | Melanoma Stage IV | Melanoma Stage III

United States
National OncoVenture
Hanmi Pharmaceutical Company Limited

Terminated

NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma

Adenocarcinoma of Lung Stage IV | Adenocarcinoma of Lung Stage IIIB

Korea, Republic of
Swedish Medical Center
GlaxoSmithKline

Completed

Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients

Stage IV Breast Cancer | Stage IV Ovarian Cancer | Ovarian Epithelial Cancer Stage III

United States
National Cancer Institute (NCI)

Completed

Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

Stage II Prostate Adenocarcinoma

United States, Canada, Hong Kong, Switzerland, India, Ireland
Pharmatech
Sanofi; Genentech, Inc.

Terminated

Phase II Avastin Trial for Stage IIIB/IV NSCLC

Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV
Synta Pharmaceuticals Corp.

Completed

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Stage IIIB Non-Small Cell Lung Cancer | Stage IV Non-Small Cell Lung Cancer

United States
Peking Union Medical College Hospital

Recruiting

A Real-world Study of Durvalumab for Lung Cancer in China

Non Small Cell Lung Cancer Stage III | Small-Cell Lung Cancer

China
Susanne Arnold
Kentucky Lung Cancer Research Program

Completed

Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
West China Hospital

Not yet recruiting

Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage ⅢA
Centre Francois Baclesse
GFPC

Recruiting

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018)

ALK Gene Rearrangement Positive | NSCLC Stage IV | NSCLC Stage IIIB | EGFR Gene Mutation | ROS1 Gene Mutation

France
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Stage IIIB Non-Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Boehringer Ingelheim

Completed

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Stage III Non-small Cell Lung Cancer

United States
AstraZeneca

Active, not recruiting

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA)

Stage IB-IIIA Non-small Cell Lung Carcinoma

United States, Italy, Netherlands, Belgium, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Brazil, Hungary, Japan, Russian Federation, Turkey, China, Korea, Republic of, Germany, Hong Kong, Spain, Australia, Israel, Ukraine, Swed...
National Cancer Institute (NCI)

Completed

Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage III Melanoma

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Recurrent Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Bladder Cancer | Stage IV Bladder Cancer | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage... and other conditions

United States
Shanghai Pulmonary Hospital, Shanghai, China

Completed

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

EGFR Gene Mutation | Lung Adenocarcinoma Stage III

China
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IV

Spain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland
Greg Durm, MD
AstraZeneca; Indiana University School of Medicine

Terminated

Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer

United States
First People's Hospital of Hangzhou

Completed

T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure

Non-small Cell Lung Cancer Stage III | Non-Small-Cell Lung Cancer Metastatic

China
First People's Hospital of Hangzhou

Completed

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

Non-small Cell Lung Cancer Stage III | Non-Small-Cell Lung Cancer Metastatic

China
Maastricht Radiation Oncology
University Medical Center Groningen; The Netherlands Cancer Institute

Completed

Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC (NVALT11)

Non Small Cell Lung Cancer (NSCLC) | Stage III Non-Small Cell Lung Cancer | Radical Treatment

Netherlands
National Cancer Institute (NCI)

Completed

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
National Cancer Institute (NCI)

Active, not recruiting

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Pancreatic Acinar Cell Carcinoma | Adult Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

Recurrent Salivary Gland Carcinoma | Salivary Gland Adenoid Cystic Carcinoma | Stage IV Major Salivary Gland Cancer AJCC v7 | Malignant Salivary Gland Neoplasm

United States, Canada
The Fourth Affiliated Hospital of Anhui Medical...

Completed

Precise Gene Signature for Predicting Outcomes in PDAC

Stage I-II Pancreatic Ductal Adenocarcinoma (PDAC) | Precise Prognostic and Predictive Signature

China
National Cancer Institute (NCI)
NRG Oncology

Completed

Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

Recurrent Breast Carcinoma | Invasive Breast Carcinoma | Metastatic Malignant Neoplasm in the Brain | Stage IV Breast Cancer AJCC v6 and v7 | HER2-Positive Breast Carcinoma

United States, Korea, Republic of, Canada
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer (InterAACT)

Anal Squamous Cell Carcinoma | Anal Basaloid Carcinoma | Anal Canal Cloacogenic Carcinoma | Metastatic Anal Canal Carcinoma | Recurrent Anal Canal Carcinoma | Stage IIIB Anal Canal Cancer | Stage IV Anal Canal Cancer

United States
Sarah Goldberg
Mirati Therapeutics Inc.

Terminated

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Lung Diseases | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Metastatic Lung Non-Small Cell Carcinoma | PD-L1 Gene Mutation | Pembrolizumab | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Advanced Treatment-Naïve PD-L1 | Sitravatinib

United States
National Cancer Institute (NCI)

Completed

Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

Fallopian Tube Cancer | Uterine Carcinosarcoma | Stage IV Ovarian Epithelial Cancer | Ovarian Sarcoma | Recurrent Uterine Sarcoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Carcinosarcoma | Female Reproductive... and other conditions

United States, Canada
University of California, Davis
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Novartis

Active, not recruiting

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

KRAS Gene Mutation | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Recurrent Non-Squamous Non-Small Cell Lung Carcinoma | Metastatic Non-Squamous Non-Small Cell Lung Carcinoma

United States
Masahiro Tsuboi
Eli Lilly and Company; Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Non-small Cell Lung Cancer Stage II | Non-small Cell Lung Cancer Stage IB | Non-small Cell Lung Cancer Stage ⅢA

Japan
National Cancer Institute (NCI)

Active, not recruiting

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Adenocarcinoma AJCC v7 | Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Prostate Adenocarcinoma With Neuroendocrine...

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR1 Gene Mutation | FGFR3 Gene Amplification

United States, Canada
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Uterine Carcinosarcoma | Recurrent Uterine Corpus Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7 | Uterine Corpus Carcinosarcoma

United States, Canada

Clinical Trials on Stage III Hypopharyngeal Carcinoma AJCC v8

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations